{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:08:48Z","timestamp":1781230128849,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03884-1","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:06:30Z","timestamp":1751364390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The delaying effect of toripalimab on disease progression in patients with advanced hepatocellular carcinoma and changes in serum tumor markers"],"prefix":"10.1186","volume":"23","author":[{"given":"Zhuo","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaomin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangxue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"1","key":"3884_CR1","doi-asserted-by":"publisher","first-page":"188314","DOI":"10.1016\/j.bbcan.2019.188314","volume":"1873","author":"D Anwanwan","year":"2020","unstructured":"Anwanwan D, et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"9","key":"3884_CR2","doi-asserted-by":"publisher","first-page":"a021535","DOI":"10.1101\/cshperspect.a021535","volume":"5","author":"CY Liu","year":"2015","unstructured":"Liu CY, Chen KF, Chen PJ. Treatment of liver Cancer. Cold Spring Harb Perspect Med. 2015;5(9):a021535.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"3884_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown ZJ, et al. Management of hepatocellular carcinoma: A review. JAMA Surg. 2023;158(4):410\u201320.","journal-title":"JAMA Surg"},{"issue":"2","key":"3884_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang X, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024;42(2):180\u201397.","journal-title":"Cancer Cell"},{"issue":"1","key":"3884_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2023.0125","volume":"30","author":"K Sankar","year":"2024","unstructured":"Sankar K, et al. Recent advances in the management of hepatocellular carcinoma. Clin Mol Hepatol. 2024;30(1):1\u201315.","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"3884_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2112187","volume":"386","author":"KS Tewari","year":"2022","unstructured":"Tewari KS, et al. Survival with Cemiplimab in recurrent cervical Cancer. N Engl J Med. 2022;386(6):544\u201355.","journal-title":"N Engl J Med"},{"issue":"11","key":"3884_CR7","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","volume":"28","author":"M Gogishvili","year":"2022","unstructured":"Gogishvili M, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022;28(11):2374\u201380.","journal-title":"Nat Med"},{"key":"3884_CR8","unstructured":"Cemiplimab in LiverTox: clinical and research information on Drug-Induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD). 2012."},{"issue":"4","key":"3884_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, et al. PD-1 Blockade with Cemiplimab in advanced cutaneous Squamous-Cell carcinoma. N Engl J Med. 2018;379(4):341\u201351.","journal-title":"N Engl J Med"},{"issue":"41","key":"3884_CR10","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1021\/acs.biochem.0c00477","volume":"59","author":"M Alannan","year":"2020","unstructured":"Alannan M, et al. Targeting lipid metabolism in liver Cancer. Biochemistry. 2020;59(41):3951\u201364.","journal-title":"Biochemistry"},{"key":"3884_CR11","doi-asserted-by":"publisher","first-page":"101386","DOI":"10.1016\/j.trim.2021.101386","volume":"66","author":"GH Chen","year":"2021","unstructured":"Chen GH, et al. Pretransplant use of Toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol. 2021;66:101386.","journal-title":"Transpl Immunol"},{"issue":"14","key":"3884_CR12","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1158\/1078-0432.CCR-24-0006","volume":"30","author":"Y Chen","year":"2024","unstructured":"Chen Y, et al. Toripalimab plus bevacizumab as First-line treatment for advanced hepatocellular carcinoma: A prospective, multicenter, Single-Arm, phase II trial. Clin Cancer Res. 2024;30(14):2937\u201344.","journal-title":"Clin Cancer Res"},{"key":"3884_CR13","doi-asserted-by":"publisher","first-page":"1113389","DOI":"10.3389\/fonc.2023.1113389","volume":"13","author":"Y Chen","year":"2023","unstructured":"Chen Y, et al. Toripalimab in combination with anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study. Front Oncol. 2023;13:1113389.","journal-title":"Front Oncol"},{"issue":"24","key":"3884_CR14","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1158\/1078-0432.CCR-23-0060","volume":"29","author":"M He","year":"2023","unstructured":"He M, et al. Lenvatinib, Toripalimab plus FOLFOX chemotherapy in hepatocellular carcinoma patients with extrahepatic metastasis: A biomolecular exploratory, phase II trial (LTSC). Clin Cancer Res. 2023;29(24):5104\u201315.","journal-title":"Clin Cancer Res"},{"key":"3884_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","volume":"174","author":"Z Lai","year":"2022","unstructured":"Lai Z, et al. Lenvatinib, Toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68\u201377.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3884_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1186\/s12885-023-11535-5","volume":"23","author":"H Lu","year":"2023","unstructured":"Lu H, et al. Efficacy and safety analysis of TACE\u2009+\u2009Donafenib\u2009+\u2009Toripalimab versus TACE\u2009+\u2009Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study. BMC Cancer. 2023;23(1):1033.","journal-title":"BMC Cancer"},{"key":"3884_CR17","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.2147\/OTT.S332351","volume":"14","author":"Y Shen","year":"2021","unstructured":"Shen Y, et al. Early prediction of objective response of fibrinogen in a Real-World cohort of hepatocellular carcinoma cases treated by programmed cell death Receptor-1 and lenvatinib. Onco Targets Ther. 2021;14:5019\u201326.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"3884_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3892\/ol.2021.12540","volume":"21","author":"J Wang","year":"2021","unstructured":"Wang J, et al. Clinical outcomes and influencing factors of PD-1\/PD-L1 in hepatocellular carcinoma. Oncol Lett. 2021;21(4):279.","journal-title":"Oncol Lett"},{"issue":"10","key":"3884_CR19","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3748\/wjg.v29.i10.1614","volume":"29","author":"YY Wang","year":"2023","unstructured":"Wang YY, et al. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. World J Gastroenterol. 2023;29(10):1614\u201326.","journal-title":"World J Gastroenterol"},{"issue":"20","key":"3884_CR20","doi-asserted-by":"publisher","first-page":"20311","DOI":"10.1002\/cam4.6602","volume":"12","author":"Z Wen","year":"2023","unstructured":"Wen Z, et al. Radiofrequency ablation combined with Toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial. Cancer Med. 2023;12(20):20311\u201320.","journal-title":"Cancer Med"},{"key":"3884_CR21","doi-asserted-by":"crossref","unstructured":"Zhang N et al. Porustobart (HBM4003) plus Toripalimab as second-line therapy in patients with advanced hepatocellular carcinoma: a multicenter, open-label, phase I study. Clin Cancer Res. 2025.","DOI":"10.1158\/1078-0432.CCR-24-3412"},{"issue":"15","key":"3884_CR22","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1158\/1078-0432.CCR-23-0410","volume":"29","author":"C Zhou","year":"2023","unstructured":"Zhou C, et al. A phase 1\/2 multicenter randomized trial of local ablation plus Toripalimab versus Toripalimab alone for previously treated unresectable hepatocellular carcinoma. Clin Cancer Res. 2023;29(15):2816\u201325.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3884_CR23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/hepr.13773","volume":"52","author":"YJ Xiang","year":"2022","unstructured":"Xiang YJ, et al. Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma. Hepatol Res. 2022;52(8):721\u20139.","journal-title":"Hepatol Res"},{"issue":"12","key":"3884_CR24","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1093\/oncolo\/oyad169","volume":"28","author":"CS Zhang","year":"2023","unstructured":"Zhang CS, et al. Anlotinib combined with Toripalimab as First-Line therapy for unresectable hepatocellular carcinoma: A prospective, multicenter, phase II study. Oncologist. 2023;28(12):e1239\u201347.","journal-title":"Oncologist"},{"key":"3884_CR25","doi-asserted-by":"publisher","first-page":"153303382110638","DOI":"10.1177\/15330338211063848","volume":"20","author":"YJ Xu","year":"2021","unstructured":"Xu YJ, et al. Toripalimab combined with hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma. Technol Cancer Res Treat. 2021;20:15330338211063848.","journal-title":"Technol Cancer Res Treat"},{"key":"3884_CR26","doi-asserted-by":"publisher","first-page":"613946","DOI":"10.3389\/fimmu.2020.613946","volume":"11","author":"G Yuan","year":"2020","unstructured":"Yuan G, et al. Development and validation of a Contrast-Enhanced CT-Based radiomics nomogram for prediction of therapeutic efficacy of Anti-PD-1 antibodies in advanced HCC patients. Front Immunol. 2020;11:613946.","journal-title":"Front Immunol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03884-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03884-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03884-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:06:32Z","timestamp":1751364392000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03884-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3884"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03884-1","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Hubei Medical College (Approval No. HMCEC-2021-032). Informed consent was obtained from all study participants. All the methods were carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}